Biogen licenses amyloid beta-related program from Denali
Fokusiert

Denali Therapeutics (NASDAQ:DNLI) added ~3% pre-market Wednesday in reaction to Biogenâs (NASDAQ:BIIB) decision to excise an option to license the companyâs Antibody Transport Vehicle (ATV): Amyloid beta program (ATV:AÎ²).
The transaction follows the recent advancement in the development of AÎ²-directed therapeutic antibodies against Alzheimerâs disease, Chief Scientific Officer of Denali (DNLI) Joseph Lewcock noted.

âOur ATV:AÎ² program is designed to safely increase exposure of the therapeutic antibody in the brain and potentially lead to improved efficacy and/or safety,â Lewcock added.
Following the transaction, Denali (DNLI) is entitled to a one-time option exercise payment in addition to development and commercial milestone payments and royalties based on future net sales.

The option exercise is part of a collaboration the two companies announced in 2020.